Medical City Children’s Hospital will soon begin offering a trial vaccine for Ewing’s Sarcoma, an aggressive and malignant tumor of the bone and soft tissue
The Mary Crowley Cancer Research Center at the hospital was approved to expand the Phase 1 FANG vaccine trial based on previous patient results. One of those patients is Carley Rutledge, a 19-year-old survivor of Ewing’s Sarcoma, who was successfully treated with the trial vaccine at Medical City Children’s. Rutledge spoke at a press conference Tuesday, along with Mary Crowley chief operating officer Shannon Cagnina.
Ewing’s Sarcoma most commonly affects children, teens, and young adults. The vaccine is designed to incorporate each person’s unique genetic characteristics, as well as identify tumor cells as foreign bodies, enhance the immune system, and block the enzyme Furin to inhibit the activity of immunosuppressor proteins. Patients who are accepted into the trial program will receive monthly injections over a 6- to 12-month period.
